Wells Fargo upgraded RxSight (RXST) to Overweight from Equal Weight with a price target of $25, up from $17.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXST:
- RxSight’s Strategic Growth and International Expansion Drive Buy Rating
- RxSight: Favorable Risk/Reward Scenario with Strong Growth Prospects and Attractive Valuation
- RxSight’s Hold Rating: Balancing Strong Gross Margins and Macroeconomic Pressures with Promising Business Models
- RxSight, Inc. Reports Strong Q1 2025 Revenue Growth
- RxSight reports Q1 adjusted EPS (3c), consensus (8c)
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue